

**Announcement
29 March 2011****Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2011 Coloplast is currently exercising a share buy-back programme of DKK 1 billion. The first part of this programme was implemented in 2010 while the second part with a total scope of up to DKK 500 million is expected to be exercised in the period 14 February – 30 September 2011.

Under the programme the following transactions have been executed during the period 21 – 25 March 2011:

Date	Number of shares	Average buying price	Amount DKK
21.3.2011	12,500	730.16	9,127,000.00
22.3.2011	5,000	724.53	3,622,650.00
23.3.2011	6,000	734.49	4,406,940.00
24.3.2011	4,000	739.75	2,959,000.00
25.3.2011	2,800	741.00	2,074,800.00
Accumulated until now under the programme	256,322	751.39	192,598,691.41

Henceforth, Coloplast owns 2,906,745 own B shares of DKK 5 equal to 6.46% of the company's total share capital.

Share buy-back in the amount of 307,401,308.59 remains under the first part of the programme.

For further information, please contact

Investors and analysts

Lene Skole
Executive Vice President, CFO
Tel. +45 4911 1700

Ian S.E. Christensen
Director of Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Henrik Nord
Investor Relations Manager
Tel. +45 4911 1800/+45 4911 3108
Email: dkhno@coloplast.com

Press and the media

Ulla Lundhus
Media Relations Manager
Tel. +45 4911 1929
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2011-03 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology and Continence Care and Wound and Skin Care. We operate globally and employ more than 7,000 people.